Join the International Society of Endocrinology ’s expert webinar
Society for Endocrinology members are also members of the International Society of Endocrinology (ISE).Register to join the ISE webinar taking place on Tuesday 26 January, at 4:00 - 5:30 PM CET, to take part in an interactive discussion with top experts. The webinar will explore the role of GLP-1 RAs in the current landscape of incretin therapies for type 2 diabetes. After the session, you will be invited to solve a CME-accredited case study on the ISE Global Education Hub, to apply what you learned. The webinar will consist of the following interactive parts:• Part 1: Have diabetes goals changed...
Source: Society for Endocrinology - January 19, 2021 Category: Endocrinology Source Type: news
Therapeutic Effects of Endogenous Incretin Hormones and Exogenous Incretin-Based Medications in Sepsis
Conclusion(s): Targeting the incretin hormone axis in sepsis may provide a means of not only promoting euglycemia in sepsis but also attenuating the proinflammatory response and improving clinical outcomes. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 4, 2020 Category: Consumer Health News Source Type: news
Vegan diets can improve insulin production in people with diabetes
A plant-based diet can improve insulin secretion and incretin hormones for people with type 2 diabetes, according to a study published in the journal Nutrients. (Source: Health News - UPI.com)
Source: Health News - UPI.com - February 27, 2019 Category: Consumer Health News Source Type: news
Plant-based meals improve insulin and incretin secretion in those with type 2 diabetes
(Physicians Committee for Responsible Medicine) A plant-based diet improves the secretion of insulin and incretin hormones in those with type 2 diabetes, according to new research published in Nutrients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 27, 2019 Category: International Medicine & Public Health Source Type: news
Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink - Gamble JM, Chibrikov E, Midodzi WK, Twells LK, Majumdar SR.
OBJECTIVES: To compare population-based incidence rates of new-onset depression or self-harm in patients initiating incretin-based therapies with that of sulfonylureas (SU) and other glucose-lowering agents. DESIGN: Population-based cohort study. S... (Source: SafetyLit)
Source: SafetyLit - October 11, 2018 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Incretin/SGLT-2 Combo Efficacy Persists 2 Years
(MedPage Today) -- Exenatide plus dapagliflozin maintained biomarker benefits in long-term study (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 26, 2018 Category: Cardiology Source Type: news
DPP-4 Inhibitors May Increase Risk for IBD in Diabetes Patients DPP-4 Inhibitors May Increase Risk for IBD in Diabetes Patients
The oral, incretin-based hypoglycemic agent was associated with a 75% increased risk for inflammatory bowel disease in adults with type 2 diabetes in a population-based study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 22, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news
Incretin Tied to Better Outcomes in NOCS - Diabetes
Prognosis for T2DM patients with NSTEMI, coronary artery stenosis improves with incretin (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 28, 2017 Category: Respiratory Medicine Tags: Cardiology, Endocrinology, Family Medicine, Geriatrics, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news
International Harrington Prize in Medicine jointly awarded to three recipients
(University Hospitals Cleveland Medical Center) The fourth annual Harrington Prize for Innovation in Medicine has been jointly awarded to Daniel J. Drucker, MD (Mount Sinai Hospital, Canada), Joel F. Habener, MD (Massachusetts General Hospital, USA) and Jens J. Holst, MD, DMSc (University of Copenhagen, Denmark) for their discovery of incretin hormones and for the translation of these findings into transformative therapies for major metabolic diseases such as diabetes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 14, 2017 Category: Global & Universal Source Type: news
Diabetes could be a warning sign of pancreatic cancer
Conclusion
This study uses a large prescription database to investigate the link between diabetes and pancreatic cancer, looking at the timing of first diabetes prescription and change in drugs prescribed.
Among people with type 2 diabetes, diagnosis of pancreatic cancer was linked with recent onset of diabetes or rapidly deteriorating diabetes. This suggests these could both be potential warning signs of hidden pancreatic cancer and indicate the need for more investigations.
While diabetes has previously been linked with pancreatic cancer, the nature of the cause and effect relationship remains unclear. It could be that d...
Source: NHS News Feed - January 31, 2017 Category: Consumer Health News Tags: Diabetes Cancer Source Type: news
[Report] Drosophila insulin release is triggered by adipose Stunted ligand to brain Methuselah receptor
Animals adapt their growth rate and body size to available nutrients by a general modulation of insulin–insulin-like growth factor signaling. In Drosophila, dietary amino acids promote the release in the hemolymph of brain insulin-like peptides (Dilps), which in turn activate systemic organ growth. Dilp secretion by insulin-producing cells involves a relay through unknown cytokines produced by fat cells. Here, we identify Methuselah (Mth) as a secretin-incretin receptor subfamily member required in the insulin-producing cells for proper nutrient coupling. We further show, using genetic and ex vivo organ culture experimen...
Source: ScienceNOW - September 29, 2016 Category: Science Authors: Renald Delanoue Source Type: news
Two incretin-based drugs linked to increased bile duct disease but not pancreatitis
At least two incretin-based drugs – glucagon-like peptide 1 agonists and dipeptidyl peptidase 4 inhibitors – do not appear to increase the risk of acute pancreatitis in individuals with diabetes but... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - August 1, 2016 Category: Endocrinology Source Type: news
Monthly News Roundup - July 2016
Injectable Adlyxin FDA-Approved for Type 2 Diabetes
The FDA has approved Sanofi’s Adlyxin (lixisenatide), a new once-daily injectable type 2 diabetes medication. Adlyxin is classified as an incretin mimetic/GLP-1 receptor agonist. For... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2016 Category: Pharmaceuticals Source Type: news
Do artificial sweeteners live up to the promise of sweetness without harm? An ongoing clinical study investigates
Scientists suspect that aspartame and other artificial sweeteners can lead to lasting, metabolic disruptions when consumed frequently, by activating specific receptors in the intestine. A clinical study is now enrolling volunteer soda drinkers to test the hypothesis. More » (Source: The Rockefeller University Newswire)
Source: The Rockefeller University Newswire - June 2, 2016 Category: Biomedical Science Authors: Geoffrey Shearer Tags: Science News aspartame blood sugar clinical trial diet soda G protein-coupled receptors incretin Laboratory of Chemical Biology and Signal Transduction metabolism study volunteers sweet receptors Thomas Huber Thomas P. Sakmar Source Type: news
No increased heart failure with incretin-based drugs
Incretin-based drugs, a type of medication used to treat type 2 diabetes, do not increase the risk of being hospitalized for heart failure relative to commonly used combinations of oral anti-diabetic drugs, according to a new study. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 24, 2016 Category: Science Source Type: news
